A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy.
BACKGROUND
Treating multiple upper facial rhytids at one time is common, but has not been researched extensively.


OBJECTIVE
We sought to compare the safety, efficacy, and effect duration of 3 botulinum neurotoxin type A (BoNTA) doses in treating multiple upper facial rhytids.


METHODS
Sixty women, randomized to 32, 64, or 96 U total doses, were assessed at baseline, week 2, week 4, then every 4 weeks. The primary efficacy measure was proportion of responders on the patient global assessment of improvement. Adverse events (AEs) were monitored.


RESULTS
All BoNTA doses were effective and safe. Significant between-group differences occurred in the percentage of responders (96 U: 71%, 64 U: 61%, 32 U: 26%; P = .0007). Adverse events did not differ significantly among groups; no serious treatment-related adverse events occurred.


CONCLUSIONS
BoNTA doses were fixed and not tailored to individuals.


CONCLUSIONS
These results confirm the efficacy and safety of 3 doses of BoNTA for treating upper facial rhytids in female patients; higher doses afforded greater benefit.
Carruthers
Alastair
A
Department of Dermatology and Skin Science, University of British Columbia, 943 W Broadway, Suite 820, Vancouver, British Columbia V5Z 4E1, Canada. alastair@carruthers.net
Carruthers
Jean
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D017060:Patient Satisfaction; D010865:Pilot Projects; D011446:Prospective Studies; D015361:Rhytidoplasty / Q000379:methods*; D013997:Time Factors
D019274:Botulinum Toxins, Type A